Want to see FR:ALCLS full AI Analyst Report?
Cellectis SA (ALCLS) AI Stock Analysis
Cellectis SA
(Paris:ALCLS)
The score is primarily constrained by weak financial performance, including declining TTM revenue, heavy losses, negative free cash flow, and higher leverage as equity has fallen. Technical indicators also point to a weak longer-term trend (below key moving averages and negative MACD). Valuation is difficult to support with a negative P/E and no dividend yield data.
Cellectis SA (ALCLS) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 250.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 368.56K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 0.67
- Revenue Growth
- -5.98%
- EPS Growth
- -8.67%
- Country
- France
- Employees
- 227
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cellectis SA Business Overview & Revenue Model
Company Description
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric...
How the Company Makes Money
Cellectis makes money primarily through (1) collaboration and license-related revenue and (2) to a lesser extent, service/other operating revenue, with limited or no recurring product sales typical of many clinical-stage biotech companies. 1) Collabo...
Cellectis SA Earnings Call Summary
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key metrics. They announced the completion of end-of-Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, and their preparation to initiate a pivotal Phase II trial in the second half of 2025. Additionally, the NatHaLi-01 study on UCART20x22 is progressing, with Phase I data anticipated by late 2025. Cellectis is advancing three cell and gene therapy programs under their partnership with AstraZeneca. Financially, the company reported cash, cash equivalents, and fixed-term deposits of $230 million as of June 30, 2025, which are expected to fund operations into the second half of 2027. They are also involved in arbitration with Servier, with a decision expected by December 15, 2025. The company will provide further insights and data during their Investor R&D Day on October 16, 2025.
Cellectis SA Financial Statement Overview
Summary
Financial statements indicate elevated risk: TTM revenue declined (-16.9%) with deeply negative profitability (net margin ~-115%), and cash flow is negative (TTM operating cash flow ~-€41.7M; free cash flow ~-€43.9M). Balance sheet leverage has increased (debt-to-equity ~2.06) as equity compressed, reducing financial flexibility despite historically solid gross margins.
Income Statement
24NegativeBalance Sheet
38NegativeCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.58M | 75.92M | 41.51M | 755.00K | 19.17M | 73.95M |
| Gross Profit | 42.25M | 55.04M | 41.51M | 18.00K | 17.40M | 37.67M |
| EBITDA | -43.63M | -21.12M | -9.46M | -92.64M | -76.38M | -78.42M |
| Net Income | -65.27M | -70.35M | -36.76M | -101.06M | -98.69M | -86.28M |
Balance Sheet | ||||||
| Total Assets | 267.37M | 324.72M | 383.54M | 334.27M | 261.22M | 382.08M |
| Cash, Cash Equivalents and Short-Term Investments | 166.85M | 208.66M | 260.31M | 203.81M | 97.70M | 186.13M |
| Total Debt | 84.57M | 90.73M | 91.46M | 85.06M | 82.85M | 102.24M |
| Total Liabilities | 226.30M | 248.85M | 252.51M | 249.57M | 135.28M | 145.60M |
| Stockholders Equity | 41.07M | 75.91M | 131.03M | 84.69M | 117.97M | 221.29M |
Cash Flow | ||||||
| Free Cash Flow | -43.86M | -44.10M | 19.15M | -25.82M | -89.89M | -124.31M |
| Operating Cash Flow | -41.69M | -41.64M | 22.99M | -24.75M | -87.44M | -104.56M |
| Investing Cash Flow | 33.13M | -30.69M | -102.81M | -15.51M | -2.76M | 7.28M |
| Financing Cash Flow | -16.31M | -16.81M | 89.11M | 82.86M | 1.15M | 47.52M |
Cellectis SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Negative. The current price of 1.04 is below the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.67, and below the 200-day MA of 2.67, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 37.98 is Neutral, neither overbought nor oversold. The STOCH value of 65.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCLS.
Cellectis SA Risk Analysis
Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCellectis SA Peers Comparison
Overall Rating
FR:IPH47Neutral
FR:NANO46Neutral
FR:TNG46Neutral
FR:OSE43Neutral- FR:ALCLS42.5Neutral
FR:MAAT39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:IPH | 47Neutral | EUR 140.30M | -2.46 | 152.56% | ― | -29.48% | 7.91% |
| FR:NANO | 46Neutral | EUR 1.43B | -25.56 | 89.71% | ― | ― | ― |
| FR:TNG | 46Neutral | EUR 202.03M | -4.34 | -29.36% | ― | 189.81% | 38.50% |
| FR:OSE | 43Neutral | EUR 45.93M | -1.16 | -96.73% | ― | -96.25% | -197.89% |
| FR:ALCLS | 43Neutral | EUR 75.07M | -1.78 | -94.14% | ― | -5.98% | -8.67% |
| FR:MAAT | 39Underperform | EUR 19.20M | -0.53 | ― | ― | -19.02% | 10.39% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALCLS | Cellectis SA | 1.04 | -1.90 | -64.63% | |
| FR:IPH | Innate Pharma S.A. | 1.26 | -0.39 | -23.51% | |
| FR:NANO | Nanobiotix SA | 28.12 | 12.36 | 78.43% | |
| FR:TNG | Transgene SA | 0.73 | -0.63 | -46.62% | |
| FR:OSE | OSE Immunotherapeutics | 1.95 | -3.75 | -65.75% | |
| FR:MAAT | MaaT Pharma | 1.02 | -3.25 | -76.16% |
Cellectis SA Corporate Events
Cellectis Showcases Promising One-Time Gene Editing Approach for Severe Hypertriglyceridemia
Cellectis has unveiled expanded preclinical data for .HEAL-101, an in vivo TALE base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress in Hamburg. The therapy uses liver-direc...
Cellectis Updates Share Capital and Voting Rights as of September 30, 2026
Cellectis reported that as of September 30, 2026, its share capital comprised 100,732,781 shares, corresponding to 105,563,044 voting rights, confirming its current capital and governance structure to the market. The updated share and voting rights d...
Cellectis pivots to in vivo gene editing and exits key CAR-T programs
Cellectis has approved a strategic shift to focus on in vivo gene editing, advancing two lead programs, .HEAL-101 and .HEAL-201, targeting severe hypertriglyceridemia and hypercholesterolemia with first Phase 1 data expected in China in 2027 and 2028...
Cellectis Plans September 14 Business Update Webcast for Global Investors
Cellectis SA will host an English- and French-language conference call and webcast on September 14, 2026 to provide a business update to investors and other stakeholders. The company plans to make a replay available on its website, underscoring its e...
Cellectis Updates Share Capital and Voting Rights as of August 31, 2026
Cellectis SA reported that as of August 31, 2026, its share capital consisted of 100,718,974 shares, corresponding to 105,568,956 voting rights. The update on capital and voting rights provides investors and market participants with greater transpare...
Cellectis Advances Allogeneic CAR-T Pipeline as Cash Runway Extends Into Late 2027
Cellectis reported progress across its allogeneic CAR-T pipeline, highlighting lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia and eti-cel for relapsed or refractory non-Hodgkin lymphoma, alongside a cash runway into the four...
Cellectis Updates Share Capital and Voting Rights as of July 31, 2026
Cellectis SA reported that its share capital comprised 100,701,207 shares as of July 31, 2026, corresponding to 105,554,794 voting rights. The updated figures clarify the company’s current capital and governance structure for shareholders and m...
Cellectis Sets August 6 Date to Release Q2 2026 Results
Cellectis announced it will release its financial results for the second quarter of 2026, covering the period ended June 30, after the close of the U.S. market on August 6. The results will be disseminated via a press release posted in the investors...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026